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Background: Prior evidence suggests a role for statins in the management of cancer. However, the benefit of statin use in the adjuvant
setting remains uncertain. This study investigates associations between statin use initiated after a breast cancer diagnosis and mortality.
Methods: Women with stage I–III breast cancer were identified from the National Cancer Registry of Ireland (N¼ 4243). Post-
diagnostic statin initiators were identified from pharmacy claims data (N¼ 837). Multivariate models were used to estimate hazard
ratios (HRs) and 95% confidence intervals (CIs) for associations between de novo statin use and mortality.
Results: The median duration of statin use was 6.7 years. No association was found between post-diagnostic statin use and breast
cancer-specific (HR 0.88, 95% CI 0.66, 1.17) or all-cause mortality (HR 1.00, 95% CI 0.82, 1.21).
Conclusions: The results from our study suggest that initiating statin use after a diagnosis of stage I–III breast cancer is not
associated with a reduction in breast cancer-specific mortality.
Statins, or 3-hydroxy-3-methylglutaryl coenzyme-A reductase
(HMGCR) inhibitors, are prescribed for cholesterol reduction
and cardiovascular disease prevention (Holmes and Chen, 2012);
however, some epidemiological evidence suggests a role in breast
cancer management (Kwan et al, 2008; Ahern et al, 2011; Chae et al,
2011; Nielsen et al, 2012; Nickels et al, 2013; Boudreau et al, 2014;
Murtola et al, 2014; Cardwell et al, 2015; Desai et al, 2015).
Uncertainty over the benefits of statins in the adjuvant breast cancer
setting remain, as significant effects may be limited to reductions in
locoregional recurrence, rather than distant recurrence (Ahern et al,
2011), and to date, no studies of statin use have reported reductions in
breast cancer-specific mortality (Nickels et al, 2013; Cardwell et al,
2015; Desai et al, 2015). Previous studies have included women who
initiated statin use prior to their breast cancer diagnosis, limiting their
utility in clinical decision making in the adjuvant setting (Ahern et al,
2011; Chae et al, 2011; Nickels et al, 2013; Boudreau et al, 2014;
Cardwell et al, 2015; Desai et al, 2015). This study aimed to:
(a) measure associations between statin use initiated after a breast
cancer diagnosis (de novo), and breast cancer-specific and all-cause
mortality, and (b) investigate whether these associations are modified
by statin solubility or tumour characteristics.
MATERIALS AND METHODS
This study used patient records from the National Cancer Registry
Ireland (NCRI), linked to individual-level prescription dispensing
data from Ireland’s Primary Care Reimbursement Services (PCRS),
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as described previously (Barron et al, 2014). The study included
women diagnosed with stage I–III invasive breast cancer (ICD-10
C50) between 1 January 2001 and 31 December 2011, aged
between 50–80 years at diagnosis, with GMS eligibility from at least
1 year prior to diagnosis and no history of invasive cancer, other
than non-melanoma skin cancer. Women receiving statin therapy
in the year prior to breast cancer diagnosis were excluded.
De novo post-diagnostic statin exposure was identified from
prescriptions dispensed between breast cancer diagnosis and end of
follow-up (death or 31 December 2012, whichever occurred first).
The number of days’ supply on each prescription was extracted
and the statin dosing intensity was calculated on the basis of the
number of days’ statin supply in the prior year (Peterson et al,
2007). These exposure histories were used to define the following
time varying exposure categories: (i) exposed (yes/no) from the
date of their first statin prescription following diagnosis; (ii) within
statin users, women were identified as having high-intensity
exposure from the date they had received a statin at an intensity of
X80%, for at least 1 year (e.g., at least 292 out of 365 days is
considered high intensity). Once allocated to an exposure category,
women remained in this category to the end of follow-up.
The following data were obtained from the NCRI database: age
(years) at diagnosis, smoking status at diagnosis (never, past,
current and unspecified), tumour stage (I, IIa, IIb, IIIa and IIIb–c),
histologic tumour grade (low, intermediate, high and unspecified),
oestrogen (ER), progesterone and human epidermal growth factor-
2 (HER2) receptor status (positive, negative and unspecified), and
chemotherapy (yes, no) in the year after diagnosis. The PCRS
database was used to identify anti-oestrogen therapy in the year
after breast cancer diagnosis (yes, no) and potentially confounding
medication use in the year prior to diagnosis (exposed, unexposed);
aspirin (Holmes et al, 2010), anti-diabetics (Holmes et al, 2010),
non-steroidal anti-inflammatory drugs (Marshall et al, 2005) and
bisphosphonates (Coleman et al, 2013). The number of drug
classes (fourth level WHO-ATC classification) dispensed in the
year before diagnosis was used as a proxy measure of comorbidity
(Schneeweiss et al, 2001). Death certificates provided the date and
cause of death (all-cause or breast cancer-specific). Breast cancer-
specific deaths were identified using SEER definitions
(Supplementary Table S1; Howlader et al, 2010).
Analyses were performed using SAS v9.3 (SAS Institute Inc,
Cary, NC, USA). The proportion of post-diagnostic statin users
was tabulated and differences in the rates of statin initiation across
covariates were compared using Poisson regression (significance at
a two-sided a-level of 0.05). Kaplan–Meier analysis was used to
estimate the median duration of statin use from initiation to the
last exposure (censored at the date of death or end of follow-up).
The overall statin exposure intensity was calculated as the number
of days’ supply as a proportion of the number of days from
initiation to last exposure.
For survival analyses, person time was calculated from the date
of breast cancer diagnosis to the end of follow-up. Multivariate Cox
proportional hazards models were used to estimate adjusted hazard
ratios (HRs) and 95% confidence intervals (CIs) for associations
between post-diagnosis statin use, and breast cancer-specific and
all-cause mortality. Statin exposure was lagged by 2 years to reduce
the possibility that changes in breast cancer prognosis or treatment
(i.e., cancer recurrence or approaching death) influenced statin
initiation or continuation (Tevaarwerk et al, 2013; Chubak et al,
2013).
Subgroup analyses included stratification by: (a) high-/low-
exposure intensity as a measure of drug adherence, (b) statin
solubility: lipophilic (atorvastatin, fluvastatin and simvastatin),
hydrophilic (pravastatin and rosuvastatin), or both, and (c) ER
status (positive, negative and unspecified). An interaction term was
included in the multivariable model to assess effect modification.
In sensitivity analyses, we defined high-intensity statin exposure as
X80% intensity for longer than two consecutive years, extended
the time without pre-diagnostic statin exposure from 1 to 3 years,
varied the lag time from 0 to 4 years and stratified lipophilic/
hydrophilic statin use by high-/low-exposure intensity.
RESULTS
Cohort and exposure characteristics. For the 4243 eligible
women, the median post-diagnostic follow-up was 4.9 years and
their characteristics are described in Table 1. A study flow diagram
is shown in Supplementary Figure S1. Within this cohort, 837
(19.7%) women initiated statin use after their breast cancer
diagnosis. Rates of initiation were significantly higher in women
with a history of diabetes, lower tumour stage at diagnosis and
positive ER status. The median time from diagnosis to statin
initiation was 2.1 years, the median duration of statin use was
6.7 years and the mean on-treatment exposure intensity was 86.3%
(Table 2). Person time attributed to de novo statin users and non-
users was 2426 and 12 369 years, respectively.
De novo statin use and mortality. No significant association was
found between de novo statin initiation, and breast cancer-specific
(HR 0.88, 95% CI 0.66, 1.17) or all-cause mortality (HR 1.00, 95%
CI 0.87, 1.18) (Table 2). Subgroup analyses in women taking statins
at an intensity of X80% for longer than 12 consecutive months
also yielded null associations with breast cancer-specific mortality
(HR 1.04, 95% CI 0.71, 1.51). The median length of time to statin
initiation in this high-intensity exposure group was 2.0 years, the
median duration of statin use was 8.5 years and the mean on-
treatment exposure intensity was 89.2%. Our results were
unchanged in sensitivity analyses (Table 3).
We found no statistically significant associations between
hydrophilic or lipophilic statin use and breast cancer-specific
mortality in subgroup analyses (Table 2). There was no evidence of
effect modification by ER status (Pinteraction¼ 0.69).
DISCUSSION
This study sought to address the clinically relevant question of
whether there is a benefit associated with statin initiation for
women following a breast cancer diagnosis. We observed no
significant association between de novo post-diagnostic statin
exposure and breast cancer-specific mortality in a cancer registry-
based cohort of 4243 women newly diagnosed with stage I–III
breast cancer. Within statin initiators, we observed long treatment
durations and high treatment intensity, suggesting that our results
are unlikely to be due to inadequate statin exposure. A statistically
significant association with reduced all-cause and breast cancer-
specific mortality was observed in the low-intensity lipophilic
statin subgroup. However, this finding is very unlikely to be causal,
as the median duration of exposure in this subgroup was only
6 months and high-intensity lipophilic statin use was not
associated with a reduction in breast cancer-specific mortality.
Several studies have examined post-diagnostic statin use in
women who initiated statin treatment prior to their breast cancer
diagnosis (Ahern et al, 2011; Chae et al, 2011; Nickels et al, 2013;
Boudreau et al, 2014; Murtola et al, 2014; Cardwell et al, 2015;
Desai et al, 2015), with some reporting large reductions in breast
cancer recurrence, in particular for lipophilic statin users (Ahern et al,
2011; Murtola et al, 2014). However, these findings may be at least
partly attributable to residual confounding due to statin-prescribing
patterns and healthy user effects. There is evidence that statins are
preferentially prescribed for, and taken by, patients who make better
healthcare choices, engage in healthier behaviours and have superior
health outcomes (Evans et al, 1995; Haley and Dietschy, 2000;
Post-diagnosis statin use and cancer mortality BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.232 593
Table 1. Characteristics of women included in the study cohort, by post-diagnosis statin exposure, with statin initiation rate
De novo statin use post breast cancer diagnosisa,b
Characteristic Non-user (N¼2759) User (N¼837)
Initiation rate (per 1000 person years),
associated P-value
Age in years
Median (IQR) 66 (58, 73) 65 (58, 72) —
Comorbidity scorec
Median (IQR) 6 (3, 11) 7 (3, 11) —
Smoking (%)
Current 583 (21.1) 171 (20.4) 41.3 0.53
Past 306 (11.1) 106 (12.7) 47.5
Never 1324 (48.0) 422 (50.4) 43.8
Unspecified 546 (19.8) 138 (16.5) 38.8
Aspirin (%)c
Yes 432 (15.7) 153 (18.3) 49.2 0.06
No 2327 (84.3) 684 (81.7) 41.6
NSAID (%)c
Yes 1178 (42.7) 384 (45.9) 44.8 0.22
No 1581 (57.3) 453 (54.1) 41.2
Anti-diabetic (%)c,d
Yes 60 (2.2) 38 (4.5) 74.7 0.001
No 2699 (97.8) 799 (95.5) 41.9
Bisphosphonate (%)c
Yes 198 (7.2) 46 (5.5) 39.4 0.40
No 2561 (92.8) 791 (94.5) 43.0
Tumour stage (%)d,e
I 917 (33.2) 297 (35.5) 44.1 0.02
IIa 843 (30.6) 297 (35.5) 47.5
IIb 610 (22.1) 162 (19.4) 38.0
IIIa 166 (6.0) 40 (4.8) 39.6
IIIb–c 223 (8.1) 41 (4.9) 31.7
Tumour grade (%)
Low 301 (10.9) 101 (12.1) 44.8 0.18
Intermediate 1357 (49.2) 416 (49.7) 43.9
High 866 (31.4) 254 (30.4) 42.4
Unspecified 235 (8.5) 66 (7.9) 35.8
ER (%)d
Negative 471 (17.1) 110 (13.1) 35.3 0.01
Positive 2028 (73.5) 610 (72.9) 43.7
Unspecified 260 (9.4) 117 (14.0) 47.5
PR (%)
Negative 717 (26.0) 179 (21.4) 39.2 0.22
Positive 1393 (50.5) 415 (49.6) 44.7
Unspecified 649 (23.5) 243 (29.0) 42.7
HER2 (%)
Negative 1679 (60.9) 419 (50.1) 40.8 0.06
Positive 339 (12.3) 99 (11.8) 44.7
Unspecified 741 (26.9) 319 (38.1) 45.1
Chemotherapy (%)f
Yes 1123 (40.7) 344 (41.1) 43.2 0.78
No 1636 (59.3) 493 (58.9) 42.5
Anti-oestrogen (%)f
Yes 2065 (74.9) 642 (76.7) 43.8 0.25
No 694 (25.1) 195 (23.3) 39.9
Abbreviations: ER¼oestrogen receptor; HER2¼ human epidermal growth factor receptor 2; IQR¼ interquartile range; NSAID¼ non-steroidal anti-inflammatory drug; PR¼progesterone
receptor.
aNo statin use in the year prior to diagnosis and at least one statin prescription received between diagnosis and the end of follow-up, 31 December 2011.
bPatients identified as statin users/non-users after lagging exposure by 2 years.
cIn the year prior to breast cancer diagnosis.
dDifference in statin initiation rate Po0.05 (Poisson regression).
eAJCC Cancer Staging Manual 6th Edition. Springer, 2002.
fIn the year post breast cancer diagnosis.
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Brookhart et al, 2007; Dormuth et al, 2009) and have a better breast
cancer prognoses (Snyder et al, 2009a, b). If unaccounted for in
analyses, this residual confounding can lead to an overestimation of
any beneficial effect of statins (Glynn et al, 2001, 2006). Moreover,
these studies included women who initiated statin use prior to their
breast cancer diagnosis, limiting the relevance of their findings to
clinical decision making in the adjuvant setting.
Although our study is larger and more methodologically robust,
our results are consistent with those from the small number of
studies that have specifically examined de novo post-diagnostic
statin use and breast cancer-specific mortality (Kwan et al, 2008;
Cardwell et al, 2015). In these studies, statin use initiated after
diagnosis was not associated with an improvement in breast cancer
outcomes. In a study by Murtola et al (Murtola et al, 2014)
investigating statin use and breast cancer survival, a sensitivity
analysis was carried out that limited their analysis to de novo statin
users. A large reduction in breast cancer mortality was observed
(HR 0.31, 95% CI 0.22, 0.44), however, this association lacked a
clear dose response. In addition, this study did not employ a lagged
statin exposure, thereby, increasing the risk of reverse causation
bias (Chubak et al, 2013). Although we observed no overall
association between de novo statin use and breast cancer-specific
mortality in an unselected population, experimental studies suggest
there may be specific subgroups of patients for whom statin
treatment could be beneficial (Garwood et al, 2010; Bjarnadottir
et al, 2013, 2015). In a study by Bjarnadottir et al (Bjarnadottir
et al, 2013, 2015), in which women received atorvastatin (80mg
per day) for 2 weeks between diagnosis and surgical resection
of their breast tumour, statin treatment was associated with a
statistically significant reduction in Ki67 proliferation index among
women with tumours expressing HMGCR. It would be worthwhile
to evaluate tumour expression of HMGCR as a predictor of
response to statin treatment in future studies.
Study strengths include the use of prospectively collected
outcome and statin exposure data, whereas limitations include
the potential for (a) residual confounding owing to a lack of
information on lifestyle factors that could influence disease
progression (i.e., obesity) and (b) misclassification bias owing to
non-adherence (although the risk is small, as women are unlikely
to continue filling a prescription they are no longer taking). A
limitation of this study is the unavailability of reliable cancer
recurrence data. Finally, the generalisability of study findings is
limited by the use of the GMS-eligible population, which is
constrained by age and socioeconomic status.
In conclusion, the results from our study suggest that initiating
statin use after a diagnosis of stage I–III breast cancer is not
significantly associated with a reduction in breast cancer-specific
mortality. We observed no evidence of effect modification by statin
solubility or hormone receptor characteristics.
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